NWBO (Northwest Biotherapeutics) Total Stockholders Equity: $-45.17 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NWBO Northwest Biotherapeutics Inc NWBO
11 GF Score
Price $0.17
! 6 Warning Signs
View Full Analysis

What is Northwest Biotherapeutics Total Stockholders Equity?

Northwest Biotherapeutics NWBO -0.97% 11 Total Stockholders Equity is $-45.17 Mil as of Jun. 2026. GuruFocus rates NWBO with a GF Score™ of 11/100. The stock has 6 warning signs investors should review.

Northwest Biotherapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $-45.17 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Northwest Biotherapeutics's Book Value per Share for the quarter that ended in Jun. 2026 was $-0.03. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Northwest Biotherapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 was -1.25.

Northwest Biotherapeutics  (OTCPK:NWBO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Northwest Biotherapeutics's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-45.174-0)/1681.338
=-0.03

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Northwest Biotherapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(33.738 + 22.703) / -45.174
=-1.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Biotherapeutics Total Stockholders Equity Related Terms

Northwest Biotherapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Northwest Biotherapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Biotherapeutics Total Stockholders Equity Chart

Northwest Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -123.99 -128.10 -65.77 -94.49 -60.28

Northwest Biotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -100.39 -108.65 -60.28 -50.54 -45.17
NWBO
11GF Score
Northwest Biotherapeutics Inc NWBO
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $-45.17 Mil mean?
Northwest Biotherapeutics (NWBO) has a Total Stockholders Equity of $-45.17 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Northwest Biotherapeutics and its competitors.
Is Northwest Biotherapeutics' Total Stockholders Equity too high?
Northwest Biotherapeutics' current Total Stockholders Equity is $-45.17 Mil. Overall, Northwest Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' Total Stockholders Equity compare to FATE and IMRX?
Northwest Biotherapeutics' Total Stockholders Equity of $-45.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Northwest Biotherapeutics and its competitors. Northwest Biotherapeutics's current Total Stockholders Equity is $-45.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Northwest Biotherapeutics (NWBO) has a current Total Stockholders Equity of $-45.17 Mil. The current Total Stockholders Equity is $-45.17 Mil. Northwest Biotherapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Northwest Biotherapeutics (NWBO), the current Total Stockholders Equity is $-45.17 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Northwest Biotherapeutics Business Description

Other Exchanges NBYB:Germany
Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
11GF Score

Get the complete analysis for NWBO

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price